Abstract | BACKGROUND: AIM: To investigate whether ADAMTS13 and VWF become useful biomarkers of treatment response in HCC patients before the initiation of HAIC treatment. METHODS: Seventy-two patients were enrolled in this study. ADAMTS13 activity (ADAMTS13:AC), VWF antigen (VWF:Ag) and VEGF levels were determined via enzyme-linked immunosorbent assay. Univariable and multivariable analyses were performed to determine the predictive factors of treatment response in patients with HCC undergoing HAIC treatment. RESULTS: ADAMTS13:AC levels in HCC patients with stable disease (SD) + partial response (PR) of HAIC treatment were significantly higher than those with progressive disease (PD) (P < 0.05). In contrast, VWF:Ag/ADAMTS13:AC ratio and VEGF levels in HCC patients with SD + PR were significantly lower than those with PD (both P < 0.05). Patients with high VWF:Ag/ADAMTS13:AC ratio (> 2.7) had higher VEGF levels than those with low ratio (≤ 2.7). Multivariable analysis revealed that VWF:Ag/ADAMTS13:AC ratio was a predictive factor of HAIC treatment response. CONCLUSION: VWF:Ag/ADAMTS13:AC ratio may become a useful biomarker of treatment response in HCC patients before the initiation of HAIC treatment.
|
Authors | Hiroaki Takaya, Tadashi Namisaki, Kei Moriya, Naotaka Shimozato, Kosuke Kaji, Hiroyuki Ogawa, Koji Ishida, Yuki Tsuji, Daisuke Kaya, Hirotestu Takagi, Yukihisa Fujinaga, Norihisa Nishimura, Yasuhiko Sawada, Hideto Kawaratani, Takemi Akahane, Masanori Matsumoto, Hitoshi Yoshiji |
Journal | World journal of gastroenterology
(World J Gastroenterol)
Vol. 26
Issue 45
Pg. 7232-7241
(Dec 07 2020)
ISSN: 2219-2840 [Electronic] United States |
PMID | 33362379
(Publication Type: Journal Article)
|
Copyright | ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
Chemical References |
- Vascular Endothelial Growth Factor A
- von Willebrand Factor
- ADAMTS13 Protein
- ADAMTS13 protein, human
|
Topics |
- ADAMTS13 Protein
- Carcinoma, Hepatocellular
(drug therapy)
- Humans
- Liver Neoplasms
(drug therapy)
- Prognosis
- Vascular Endothelial Growth Factor A
- von Willebrand Factor
|